Next Generation Sequencing Services Market (2026-2036)

The growth of this market is mainly driven by the declining cost of sequencing, the rising prevalence of cancer and the growing use of genomic profiling in treatment selection, the high cost of building in-house sequencing capacity, national genome sequencing programs, and the increasing use of sequencing in drug development. In addition, the expansion of clinical sequencing in reproductive health, rare diseases, and infectious diseases, the growth of long-read, single-cell, and multiomic services, and the return of laboratory developed tests to CLIA oversight in the U.S. are further supporting the growth of this market.

The global NGS Services Market is projected to reach USD 33,728.0 million by 2036, driven by falling sequencing costs, rising cancer incidence and genomic profiling, the high cost of in-house capacity, national genome programs, and outsourced sequencing in drug development.

North America is expected to account for the largest market share of 44.0% in 2026, while Asia-Pacific is projected to register the fastest growth at a CAGR of 17.5% during the forecast period, and India is projected to register the highest CAGR of any country, at 19.7%.

By type, Targeted Sequencing Services are expected to account for the largest market share of 27.2% in 2026, whereas Methyl Sequencing Services are projected to register the highest CAGR of 15.6%, followed by Whole Genome Sequencing Services at 15.4%.

By technology, Sequencing by Synthesis is expected to account for the largest share of 63.5% in 2026, while Nanopore Sequencing is projected to register the highest CAGR of 15.6% during the forecast period.

Clinical demand has become the main source of growth. Natera reported total revenue of USD 2,306.1 million in 2025, up 35.9%, Guardant Health reported about 276,000 oncology tests, up 34%, and GeneDx reported 97,271 exome and genome tests, up 30.5%.

Sequencing-based tests moved into standard care pathways in 2026. The FDA approved Signatera CDx as the first companion diagnostic in blood-based MRD in May 2026, and the Shield blood test entered the American Cancer Society colorectal cancer screening guidelines in the same month, with UnitedHealthcare coverage from August 2026 extending access to about 70 million lives.

The cost of sequencing a human genome has fallen from about USD 29,092 in 2010 to approximately USD 200 on current high-throughput platforms, while production systems still cost around USD 1 million and reach their stated cost per genome only at full capacity, which favors centralized service providers.

The NGS Services Market comprises next-generation sequencing performed on a contract basis for pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, academic institutes, and other users that do not operate their own platforms or need specialized capacity. The market includes targeted sequencing, RNA sequencing, whole genome sequencing, exome sequencing, de novo sequencing, methyl sequencing, ChIP sequencing, and other NGS services, delivered on sequencing by synthesis, ion semiconductor, single-molecule real-time (SMRT), nanopore, and DNA nanoball platforms. The market ecosystem extends from platform and reagent suppliers to sample collection and logistics, library preparation and sequencing, data analysis and interpretation, and the clinicians and researchers who act on results.

The economics of sequencing favor service providers. The first human genome cost approximately USD 2.7 billion to sequence in 2003, and according to the National Human Genome Research Institute (NHGRI), the cost per genome fell from about USD 29,092 in 2010 to USD 562 in 2021; high-throughput platforms now deliver a genome at approximately USD 200. However, high-throughput production systems carry list prices around USD 1 million, mid-throughput benchtop systems USD 275,000 to USD 350,000, and even low-throughput systems close to USD 100,000, and the stated cost per genome is reached only at full capacity. Centralized providers that run instruments at high utilization can therefore offer lower prices than most individual laboratories.

Clinical demand has become the main source of growth. Illumina reported that more than 65% of its sequencing consumables revenue now comes from clinical applications, including comprehensive genomic profiling, rare disease genome sequencing, and prenatal testing, while research and applied consumables declined 12%. Natera processed more than one million tests in each of the first two quarters of 2026 and raised its 2026 revenue guidance to USD 2.85 billion to USD 2.91 billion. By contrast, research demand has been held back by funding pressure, including the proposed cut of nearly 40% to the National Institutes of Health budget for fiscal 2026.

Regulatory and policy changes are reshaping the market. On March 31, 2025, a U.S. District Court vacated the FDA rule that would have regulated laboratory developed tests as medical devices, and the FDA issued a final rule on September 19, 2025, reverting its regulation to the text in effect before May 2024, keeping most clinical sequencing under CLIA oversight. On December 18, 2025, the BIOSECURE Act was signed into law, prohibiting U.S. federal agencies from procuring biotechnology equipment or services from designated companies of concern, which include BGI Genomics and MGI Tech.

On the supply side, sequencing is no longer dominated by a single technology. Roche launched the AXELIOS 1 sequencing platform in June 2026, Element Biosciences and Ultima Genomics launched new high-throughput platforms in February 2026, and PacBio lowered the list price of a long-read genome to USD 345, which is expected to reduce the cost base of service providers and expand demand for long-read, single-cell, and multiomic services.

The cost of sequencing a human genome has fallen by more than four orders of magnitude. According to the NHGRI, the cost per genome fell from about USD 29,092 in 2010 to USD 562 in 2021, and high-throughput short-read platforms now deliver a genome at approximately USD 200. Lower costs have made sequencing viable for large research studies, population programs, and routine clinical testing, and service providers that operate high-throughput platforms at full capacity are best placed to pass these savings on to customers.

According to the International Agency for Research on Cancer (IARC), there were about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and IARC projects over 35 million new cancer cases in 2050, an increase of 77%. Comprehensive genomic profiling, liquid biopsy, and minimal residual disease (MRD) testing are becoming standard parts of cancer care, and most of this testing is performed by specialized service laboratories such as Natera, Guardant Health, Foundation Medicine, and Labcorp. Guardant Health reported about 276,000 oncology tests in 2025, up 34%.

Although the cost per genome has declined, the capital and operating cost of sequencing capacity remains high, with production systems priced around USD 1 million and additional investment required for library preparation automation, data storage, and computing. At the same time, national population sequencing programs procure sequencing at a scale that single institutions do not reach, and much of this work is performed by service providers and national sequencing centers. Genomics England sequenced 100,000 genomes from about 85,000 patients under its 100,000 Genomes Project, and the Emirati Genome Programme has sequenced more than 800,000 genomes since 2019.

Several established and lower-cost methods compete with NGS for specific questions. Polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), microarrays, and Sanger sequencing are used to detect known variants, fusions, and copy number changes, and Sanger sequencing remains the standard for single-gene work and confirmation, with read lengths of 800 to 1,000 base pairs at high accuracy.

Sequencing services need personnel trained in library preparation, instrument operation, bioinformatics, and clinical interpretation. Interpretation is the most constrained step, because classifying a variant as pathogenic, benign, or of uncertain significance requires clinical genetics expertise that takes years to build, which limits the capacity of providers to scale clinical services.

Clinical sequencing has moved beyond oncology. Non-invasive prenatal testing based on cell-free DNA is offered to pregnant women across the U.S., Europe, and Asia, and expanded carrier screening panels are increasingly offered before conception. In rare diseases, exome and genome sequencing have become first-tier tests for children with suspected genetic disorders, and GeneDx reported 97,271 exome and genome tests in 2025, up 30.5%. Pathogen genomic surveillance networks built during the COVID-19 pandemic are also extending sequencing into infectious disease testing.

Long-read sequencing produces reads of 10 to 100 kilobases and above, which resolves structural variants, repeat expansions, phasing, and methylation that short reads characterize incompletely, and single-cell and spatial sequencing measure gene expression cell by cell or by tissue location. These methods need specialized instruments, such as the PacBio Revio or Oxford Nanopore PromethION, and experienced staff, so most customers buy them as a service. BGI Genomics reported spatial and single-cell sequencing services up 79% and 57% in the first half of 2026.

The vacatur of the FDA rule on laboratory developed tests in March 2025, followed by the FDA final rule of September 19, 2025, reverting its regulation to the text in effect before May 2024, removed the prospect of device-level premarket review for most laboratory developed sequencing tests in the U.S. This lowers the cost and time required for clinical service laboratories to launch new sequencing-based tests.

As sequencing costs fall, large hospital networks, academic medical centers, and research institutes are installing their own sequencers to shorten turnaround times, keep samples and data in-house, and capture test revenue. Benchtop systems priced at USD 275,000 to USD 350,000 make this feasible for mid-sized laboratories, and FDA-cleared or CE-IVD marked oncology panels on these platforms allow hospitals to decentralize testing.

A 30x human genome generates about 100 gigabytes of raw data, and service providers that ship samples and data across borders must meet the General Data Protection Regulation in Europe, the Health Insurance Portability and Accountability Act in the U.S., and national rules such as the regulations on human genetic resources in China. In addition, the BIOSECURE Act, signed into law on December 18, 2025, bars U.S. federal agencies, contractors, and grant recipients from using equipment or services from designated companies of concern in funded work, which affects providers such as BGI Genomics.

Clinical and research sequencing demand have followed different paths. Illumina reported that clinical sequencing consumables grew 20% excluding China for two consecutive quarters and that more than 65% of its sequencing consumables revenue now comes from clinical applications, while research and applied consumables declined 12%.

Roche launched the AXELIOS 1 sequencing platform in June 2026, built on sequencing by expansion chemistry, with company data showing 2.3 terabases of concordant duplex bases per four-hour run. Element Biosciences (AVITI), Ultima Genomics (UG100), and MGI Tech (DNBSEQ) compete on cost per gigabase, and Oxford Nanopore Technologies reported revenue of approximately GBP 223.5 million in fiscal 2025, increasing competition and lowering the cost base of service providers.

A series of decisions in 2026 moved sequencing-based tests from specialist use into standard pathways. In May 2026, the FDA approved Signatera CDx as the first companion diagnostic in blood-based MRD, and the NCCN issued a Category 1 recommendation for MRD-guided adjuvant atezolizumab in bladder cancer. In the same month, the American Cancer Society added the Shield blood test to its colorectal cancer screening guidelines, and UnitedHealthcare began covering it from August 2026, bringing coverage to about 70 million lives.

Based on type, the global NGS Services Market is segmented into Targeted Sequencing Services, RNA Sequencing Services, Whole Genome Sequencing Services, Exome Sequencing Services, De Novo Sequencing Services, Methyl Sequencing Services, ChIP Sequencing Services, and Other NGS Services. In 2026, the Targeted Sequencing Services segment is expected to account for the largest share of 27.2% of the global NGS Services Market. The large share of this segment is mainly due to the lower cost, higher depth, and routine clinical use of targeted panels in cancer genomic profiling and liquid biopsy. However, the Methyl Sequencing Services segment is projected to register the highest CAGR of 15.6% during the forecast period, driven by blood-based cancer screening built on methylation signals, followed by Whole Genome Sequencing Services at 15.4%.

Based on technology, the market is segmented into Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, and DNA Nanoball Sequencing. In 2026, Sequencing by Synthesis is expected to account for the largest share of 63.5% of the NGS services market, because of the large installed base of Illumina platforms at service providers and their low cost per base. However, Nanopore Sequencing is projected to register the highest CAGR of 15.6% during the forecast period.

Based on application, the market is segmented into Research Applications (Drug Discovery, Agriculture & Animal Research, and Other Research Applications) and Clinical Applications (Oncology, Reproductive Health, Infectious Diseases, and Other Clinical Applications). In 2026, the Research Applications segment is expected to account for the larger share of 55.5% of the NGS services market, because of the heavy use of outsourced sequencing in drug discovery and development. However, the Clinical Applications segment is projected to register the higher CAGR of 15.9% during the forecast period, and within it Oncology is projected to register the highest CAGR of 16.8%.

Based on end user, the market is segmented into Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic Institutes & Research Centers, and Other End Users. In 2026, the Hospitals & Diagnostic Laboratories segment is expected to account for the largest share of 44.9% of the NGS services market due to the concentration of complex clinical sequencing in specialized reference laboratories. This segment is also projected to register the highest CAGR of 15.7% during the forecast period.

The global NGS Services Market combines clinical sequencing laboratories, commercial genomics and contract research providers, and platform companies that offer sequencing services. Market participants compete primarily on test menu and service breadth, turnaround time, data quality, regulatory approvals and payer coverage, price per sample, bioinformatics and interpretation capability, and geographic reach.

Regulatory approvals and coverage decisions were among the most frequent strategic developments between January 2025 and September 2026, reflecting the growing importance of clinical services, including the FDA approval of Signatera CDx, three companion diagnostic approvals for FoundationOne CDx, and the inclusion of Shield in the American Cancer Society guidelines. Natera, Guardant Health, and Roche (through Foundation Medicine) lead the market ranking in 2025, followed by BGI Genomics and Labcorp.

The report provides a comprehensive competitive assessment of the leading companies operating in the global NGS Services Market. The key players profiled in the report include Illumina, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), Labcorp Holdings Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BGI Genomics Co., Ltd. (China), Novogene Co., Ltd. (China), Revvity, Inc. (U.S.), Macrogen, Inc. (South Korea), QIAGEN N.V. (Netherlands), Azenta, Inc. (U.S.), GeneDx Holdings Corp. (U.S.), Natera, Inc. (U.S.), Guardant Health, Inc. (U.S.), and Quest Diagnostics Incorporated (U.S.).